Although I am usually not inclined to posit speculations on why a particular drug does or doesn't do something, in this case I will. Im guessing that the higher doses of Anadrol cause enough appetite suppression (at least anecdotally) to make eating rather difficult. It can also increase insulin resistance and glucose intolerance (5). This has the effect of making macronutrient absorption more inefficient, and could also be a factor in reducing gains when the dosage goes over 100mgs/day. Unfortunately, Anadrol also has a reasonably profound effect on your body's natural hormonal system, on par with most other oral steroids , but not as bad as most injectables, and its certainly not as harsh on your lipid profile as many anabolics are
The mixture of testosterone is subject to the effects of the enzyme aromatase in the body, among the side effects of T-400 are side effects of estrogen. The rate of aromatization is directly related to the amount of used substance, and together with increasing doses aromatization is higher. Estrogenic side effects include: excessive water retention and bloating, elevated blood pressure (. due to water retention in the body), accelerated fat deposition and gynecomastia. The side effects of estrogen can be reduced or completely avoided by using aromatase inhibitors or SERMs (selective estrogen receptor modulators. Among androgenic side effects are: increased secretion of sebum (oily skin), acne (in terms of increased secretion of sebum), body hair growth, and increased risk of inducing male pattern baldness (MPB) in persons with a genetic predisposition. Anabolic / androgenic steroids can have deleterious effects on blood cholesterol levels. This includes a tendency to reduce HDL (good) cholesterol and increase LDL (bad) cholesterol. All anabolic steroids have the ability to suppress or shut down the natural endogenous production of testosterone in the body, and T-400 is no exception. After the end of the cycle, it is highly recommended to use a suitable PCT (Post Cycle Therapy).
CAUTION SHOULD BE EXERCISED WHEN ADMINISTERING PROMETHAZINE PRODUCTS TO PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER BECAUSE OF THE POTENTIAL FOR FATAL RESPIRATORY DEPRESSION. RESPIRATORY DEPRESSION AND APNEA, SOMETIMES ASSOCIATED WITH DEATH, ARE STRONGLY ASSOCIATED WITH PROMETHAZINE PRODUCTS AND ARE NOT DIRECTLY RELATED TO INDIVIDUALIZED WEIGHT-BASED DOSING, WHICH MIGHT OTHERWISE PERMIT SAFE ADMINISTRATION. CONCOMITANT ADMINISTRATION OF PROMETHAZINE PRODUCTS WITH OTHER RESPIRATORY DEPRESSANTS HAS AN ASSOCIATION WITH RESPIRATORY DEPRESSION, AND SOMETIMES DEATH, IN PEDIATRIC PATIENTS.